Visceral leishmaniasis complicated by hemophagocytic lymphohistiocytosis: A case report from a nonendemic area

KEY CLINICAL MESSAGE: Visceral leishmaniasis and hemophagocytic lymphohistiocytosis share many features in common and may coincide in the same patient. Timely diagnosis and management of visceral leishmaniasis could save patients from unnecessary toxic treatment. ABSTRACT: Visceral leishmaniasis and...

Descripción completa

Detalles Bibliográficos
Autores principales: Joudeh, Anwar I., Elsiddig Awadelkarim, Hussein A., Gul, Mohammadshah Isam, Elayana, Mahmoud Salm, Soliman, Dina Sameh, Amer, Aliaa, Alsamawi, Musaed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160431/
https://www.ncbi.nlm.nih.gov/pubmed/37151937
http://dx.doi.org/10.1002/ccr3.7309
Descripción
Sumario:KEY CLINICAL MESSAGE: Visceral leishmaniasis and hemophagocytic lymphohistiocytosis share many features in common and may coincide in the same patient. Timely diagnosis and management of visceral leishmaniasis could save patients from unnecessary toxic treatment. ABSTRACT: Visceral leishmaniasis and hemophagocytic lymphohistiocytosis share many clinical features in common and may coexist in the same patient. Visceral leishmaniasis should be promptly ruled out in patients coming from endemic areas before starting immunosuppressive therapy for hemophagocytic lymphohistiocytosis. The mainstay treatment, in this case, is anti‐leishmania medications preferably liposomal amphotericin‐B.

Ejemplares similares